Page last updated: 2024-12-05
octamethylcyclotetrasiloxane
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
octamethylcyclotetrasiloxane: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
octamethylcyclotetrasiloxane : A cyclosiloxane that is the octamethyl derivative of cyclotetrasiloxane. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11169 |
| CHEMBL ID | 1869229 |
| CHEBI ID | 25640 |
| SCHEMBL ID | 18354 |
| MeSH ID | M0081975 |
Synonyms (70)
| Synonym |
|---|
| BIDD:ER0157 |
| AKOS008901191 |
| oktamethylcyklotetrasiloxan |
| octamethylcyclotetrasiloxane |
| nsc-345674 |
| 556-67-2 |
| nsc345674 |
| cyclotetrasiloxane, octamethyl- |
| einecs 209-136-7 |
| kf 994 |
| oktamethylcyklotetrasiloxan [czech] |
| vs 7207 |
| sf 1173 |
| hsdb 6131 |
| nuc silicone vs 7207 |
| uc 7207 |
| brn 1787074 |
| silicone sf 1173 |
| ccris 1327 |
| union carbide 7207 |
| nsc 345674 |
| omcts |
| CHEBI:25640 , |
| 2,2,4,4,6,6,8,8-octamethyl-1,3,5,7,2,4,6,8-tetroxatetrasilocane |
| 2,2,4,4,6,6,8,8-octamethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane |
| cyclic dimethylsiloxane tetramer |
| oktamethylzyklotetrasiloxan |
| octamethylcyclotetrasiloxane, 98% |
| NCGC00164099-01 |
| inchi=1/c8h24o4si4/c1-13(2)9-14(3,4)11-16(7,8)12-15(5,6)10-13/h1-8h3 |
| hmmgmwaxvfquoa-uhfffaoysa- |
| BMSE000765 |
| O0142 |
| dimethylsiloxane cyclic tetramer |
| NCGC00164099-03 |
| NCGC00164099-02 |
| cas-556-67-2 |
| dtxsid7027205 , |
| NCGC00258949-01 |
| dtxcid107205 |
| NCGC00254406-01 |
| tox21_300547 |
| tox21_201398 |
| FT-0688100 |
| cyclotetrasiloxane, 2,2,4,4,6,6,8,8-octamethyl- |
| cz227117je , |
| ec 209-136-7 |
| unii-cz227117je |
| d-4 |
| octamethycyclotetrasiloxane |
| cyclomethicone 4 |
| octamethylcyclotetrasiloxane [mi] |
| cyclotetrasiloxane [inci] |
| cyclomethicone 4 [usp-rs] |
| octamethylcyclotetrasiloxane [hsdb] |
| SCHEMBL18354 |
| CHEMBL1869229 |
| octamethyl cyclotetrasiloxane |
| co9810 |
| HMMGMWAXVFQUOA-UHFFFAOYSA-N |
| o9810 |
| 2,2,4,4,6,6,8,8-octamethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane # |
| mfcd00003269 |
| cyclomethicone 4, united states pharmacopeia (usp) reference standard |
| octamethylcyclotetrasiloxane, analytical standard |
| d4 cyclomethicone, pharmaceutical secondary standard; certified reference material |
| octamethyl-cyclotetrasiloxane |
| Q2013804 |
| F83065 |
| CS-0213747 |
Research Excerpts
Overview
Octamethylcyclotetrasiloxane (D4) is a cyclic siloxane primarily used as a monomer or intermediate in the production of silicone polymers. It is a low viscosity, silicone fluid consisting of four dimethyl-siloxy units ((CH3)2SiO)4.
Effects
Octamethylcyclotetrasiloxane (D4) has been used for more than 40 years in industrial applications and consumer products. It has been shown to have effects on the female rat reproductive cycle.
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " No adverse genetic findings were seen in the in vivo screen for chromosome aberrations." | ( Genetic toxicity evaluation of octamethylcyclotetrasiloxane. Barfknecht, TR; Jung, R; Reynolds, VL; Thakur, AK; Vergnes, JS, 2000) | 0.59 |
| " No adverse effects were observed at any exposure level on anogenital distance, vaginal patency and preputial separation." | ( A two-generation reproductive toxicity study of octamethylcyclotetrasiloxane (D4) in rats exposed by whole-body vapor inhalation. Holson, JF; Meeks, RG; Plotzke, KP; Siddiqui, WH; Stump, DG, 2007) | 0.6 |
| ", carcinogenic, mutagenic, or toxic for reproduction) substance nor be regarded as an endocrine disruptor." | ( Assessing modes of action, measures of tissue dose and human relevance of rodent toxicity endpoints with octamethylcyclotetrasiloxane (D4). Andersen, ME, 2022) | 0.94 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " We first applied a basic physiologically based pharmacokinetic (PBPK) model (J." | ( Physiological modeling reveals novel pharmacokinetic behavior for inhaled octamethylcyclotetrasiloxane in rats. Andersen, ME; Dobrev, ID; Gallavan, RH; Plotzke, KP; Reitz, RH; Sarangapani, R, 2001) | 0.54 |
| "A physiologically based pharmacokinetic model was developed to describe the silicone constituent octamethylcyclotetrasiloxane (D4) and its migration from intact or ruptured silicone gel-filled breast implants into surrounding tissues." | ( Physiologically based pharmacokinetic modeling of the disposition of octamethylcyclotetrasiloxane (D4) migration from implants in humans. Corley, RA; Powell, T; Soelberg, JJ; Thrall, KD, 2008) | 0.8 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "Removing volatile methyl siloxanes (VMSs) from biogas remains a longstanding challenge in the field of biological process due to their low bioavailability and biodegradation." | ( Siloxanes removal from biogas by a lab-scale biotrickling filter inoculated with Pseudomonas aeruginosa S240. Li, Y; Xu, J; Zhang, W, 2014) | 0.4 |
Dosage Studied
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| organosilicon compound | An organosilicon compound is a compound containing at least one carbon-silicon bond. |
| cyclosiloxane | Compounds having rings of alternating silicon and oxygen atoms. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 28.1838 | 0.0002 | 14.3764 | 60.0339 | AID588533 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 13.6854 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 61.6448 | 0.0010 | 24.5048 | 61.6448 | AID743212 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 55.3914 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 21.9549 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (124)
Molecular Functions (34)
Ceullar Components (19)
Research
Studies (104)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (0.96) | 18.7374 |
| 1990's | 12 (11.54) | 18.2507 |
| 2000's | 31 (29.81) | 29.6817 |
| 2010's | 50 (48.08) | 24.3611 |
| 2020's | 10 (9.62) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 51.00
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (51.00) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (2.80%) | 5.53% |
| Reviews | 3 (2.80%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 101 (94.39%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||